Results 241 to 250 of about 53,924 (268)

Cystatin C and intravenous thrombolysis

European Journal of Neurology, 2021
With great interest, we read the recent original article written by Zihan Chang et al1 , which was published in European Journal of Neurology. In this multicenter retrospective case-control study, the authors found that elevated serum Cystatin C may be associated with unfavorable clinical outcomes after intravenous tissue plasminogen activator therapy,
Meidi Peng, Yupei Chen, Guiling Geng
openaire   +2 more sources

Beyond Intravenous Thrombolysis

CNS Spectrums, 2007
ABSTRACTThe National Institute of Neurological Disorders and Stroke trial of recombinant tissue plasminogen activator has been considered a landmark study in the acute treatment of ischemic stroke. Unfortunately, only a small percentage of all ischemic stroke patients presents to the hospital in time to receive the drug.
Srikanth Muppidi, Carissa Pineda, Rodney Bell, David G. Brock, Farhan Siddiq, Kiwon Lee   +5 more
openaire   +3 more sources

Intravenous thrombolysis in Sneddon’s syndrome

Journal of Clinical Neuroscience, 2012
Sneddon's syndrome (SS) is an uncommon disorder, characterized by the association of ischemic stroke and widespread livedo reticularis. The treatment options for SS to prevent stroke recurrence and future disability include antiplatelet therapy, anticoagulation, or immunosuppression.
Feng Gao, Min Lou, Jianzhong Sun, Jihua Wang, Magdy Selim, Fanhui Zhang   +5 more
openaire   +3 more sources

Intravenous thrombolysis for acute stroke

Neurology, 1997
Until recently there was no specific therapy for stroke, but the recent publication of the National Institute of Neurological Disorders and Stroke(NINDS) t-PA for Acute Stroke Trial presents the first effective, specific therapy for stroke.1 In considering whether to apply thrombolysis to any given patient, the physician must consider the factors ...
Patrick D. Lyden, James C. Grotta, Thomas G. Brott, Michael Frankel, Steven R. Levine, John R. Marler   +5 more
openaire   +3 more sources

Intravenous Thrombolysis in Acute Myocardial Infarction

Chest, 2001
(CHEST 2001; 119:253S‐277S) F ibrinolytic therapy for acute myocardial infarction (MI) has been one of the most potent treatments ever developed for a condition that kills more patients worldwide than any other. This review will focus on approved agents and the randomized trials that have led to their widespread use.
Ohman E., Harrington R., Cannon C., AGNELLI, Giancarlo, Cairns J., Kennedy J.   +5 more
openaire   +4 more sources

Intravenous (IV) Thrombolysis

2010
This chapter will review the basic mechanisms of clot formation (thrombosis) and dissolution (thrombolysis or fibrinolysis), the mechanisms of the major drug classes used in the treatment, and the results from major clinical trials. This chapter will also present ­evidence-based recommendations and protocols for applying thrombolytic therapy to ...
Lee H. Schwamm, Raul G. Nogueira
openaire   +2 more sources

Intravenous thrombolysis for stroke

BMJ, 2010
Elderly patients should not be excluded solely on the basis of age Intravenous thrombolytic treatment for acute ischaemic stroke is controversial in patients over 80 years, mainly because they have been excluded from or under-represented in the large scale randomised controlled trials of such treatment.1 2 3 In the linked study (doi:10.1136/bmj.c6046),
openaire   +2 more sources

Intravenous Thrombolysis for Acute Ischemic Stroke

CONTINUUM: Lifelong Learning in Neurology, 2023
ABSTRACT OBJECTIVE This article reviews the history of IV thrombolysis, its current indications and implementation, the duality of the “time is brain” versus “tissue clock” approaches, the impact of endovascular thrombectomy on IV thrombolysis, the emergence of tenecteplase, and future research directions.
openaire   +2 more sources

Coronary Thrombolysis with Intravenous Streptokinase

Cardiology Clinics, 1987
Coronary thrombolysis can be achieved with several lytic agents administered via the intravenous or intracoronary routes. Streptokinase, when administered intravenously, produces coronary thrombolysis in from 34 to 75 per cent of patients. Intravenous administration has the advantage of rapid administration without the risks or delays inherent in the ...
openaire   +3 more sources

Analyses of the Turkish National Intravenous Thrombolysis Registry

Journal of Stroke and Cerebrovascular Diseases, 2016
The relatively late approval of use of recombinant tissue plasminogen activator (rt-PA) for acute ischemic stroke in Turkey has resulted in obvious underuse of this treatment. Here we present the analyses of the nationwide registry, which was created to prompt wider use of intravenous thrombolysis, as well as to monitor safe implementation of the ...
Kursad Kutluk, Dilaver Kaya, Nazire Afsar, Ethem Murat Arsava, Vesile Ozturk, Nevzat Uzuner, Semih Giray, Mehmet Akif Topcuoglu, Levent Gungor, Hadiye Sirin, Erdem Yaka, Ozcan Ozdemir, Turgay Dalkara   +12 more
openaire   +5 more sources